Get the Stockscreener App
0.6799
0.00%
0.00
Gt Biopharma Inc stock is traded at $0.6799, with a volume of 551.54K.
It is up +0.00% in the last 24 hours and down -15.54% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$0.6799
Open:
$0.7
24h Volume:
551.54K
Relative Volume:
0.38
Market Cap:
$2.54M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.0982
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
-3.72%
1M Performance:
-15.54%
6M Performance:
-69.51%
1Y Performance:
-66.83%
1-Day Range:
$0.68
$0.7299
1-Week Range:
$0.6443
$1.37
52-Week Range:
$0.55
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.75 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.88 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.55 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2011 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.02 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Will GT Biopharma Inc. stock benefit from automationM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Tools to assess GT Biopharma Inc.’s risk profile2025 Market Outlook & Momentum Based Trading Ideas - newser.com
Visual trend scoring systems applied to GT Biopharma Inc.Earnings Overview Summary & Low Drawdown Momentum Trade Ideas - newser.com
Strategies to average down on GT Biopharma Inc.Fed Meeting & Safe Entry Zone Tips - newser.com
Will GT Biopharma Inc. continue its uptrendQuarterly Market Summary & Advanced Swing Trade Entry Alerts - newser.com
GT Biopharma Inc OXIA Stock Analysis and ForecastEconomic Data Impact & Investment Recommendations You Can Trust - earlytimes.in
Chart based analysis of GT Biopharma Inc. trendsStop Loss & Weekly High Potential Stock Alerts - newser.com
Using economic indicators to assess GT Biopharma Inc. potentialMarket Growth Summary & Breakout Confirmation Alerts - newser.com
GT Biopharma Inc. stock volume spike explainedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Will GT Biopharma Inc. (OXIA) stock test record highs in 2025Quarterly Trade Report & Trade Opportunity Analysis Reports - newser.com
GT Biopharma Inc. stock trend forecastWeekly Profit Report & Fast Moving Market Watchlists - newser.com
Why GT Biopharma Inc. stock is seen as undervaluedPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits
Using data filters to optimize entry into GT Biopharma Inc.Insider Selling & Consistent Profit Alerts - newser.com
GT Biopharma advances Phase 1 trial of NK cell therapy with no safety issues - Investing.com Nigeria
Stocks In Play: GT Biopharma Inc - Barchart.com
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 - 富途牛牛
GT Biopharma provides enrollment update on GTB-3650 Phase 1 trial in patients with relapsed or refractory (R/R) CD33 expressing hematologic malignancies - MarketScreener
GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 - GlobeNewswire
GT Biopharma Initiates Cohort 3 Dosing; No DLTs, Cohort 4 Planned | GTBP Stock News - Stock Titan
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Yahoo Finance
GT Biopharma Inc - Menafn.com
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion - MarketScreener
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms - Eastern Progress
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction - The Globe and Mail
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit - GlobeNewswire
Oct 28–29: GT Biopharma CEO Michael Breen to Attend Bahamas Summit; One-on-one Meetings Available - Stock Titan
Key metrics from GT Biopharma Inc.’s quarterly dataBond Market & Weekly Momentum Stock Picks - newser.com
How GT Biopharma Inc. (OXIA) stock reacts to new regulationsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
What’s the recovery path for long term holders of GT Biopharma Inc.Market Volume Summary & Expert Curated Trade Setups - newser.com
What drives GT Biopharma Inc stock priceChart Pattern Recognition & Small Capital Trading Growth - earlytimes.in
Will GT Biopharma Inc. (OXIA) stock profit from automation wave2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
GT Biopharma Inc Stock Analysis and ForecastHead and Shoulders Patterns & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Can swing trading help recover from GT Biopharma Inc. lossesTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):